|Doubt cast on wisdom of targeting 'bad' cholesterol to curb heart disease risk|
Added: 03.08.2020 23:41 | 0 views | 0 comments
Setting targets for 'bad' (LDL) cholesterol levels to ward off heart disease and death in those at risk might seem intuitive, but decades of research have failed to show any consistent benefit for this approach, reveals an analysis of the available data.
|Psoriasis drug target offers potential for osteosarcoma|
Added: 18.09.2019 14:30 | 0 views | 0 comments
A treatment for psoriasis could be repurposed to treat a rare but aggressive form of youth cancer, new findings suggest.
|Some biologic treatments for psoriasis may be safer for patients|
Added: 11.05.2019 13:39 | 0 views | 0 comments
Dermatologists found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.
|People with COPD suffer fewer lung-related problems when treated with targeted lung denervation|
Added: 18.09.2018 0:19 | 0 views | 0 comments
First results from a clinical trial of a procedure to open obstructed airways in patients with chronic obstructive pulmonary disease (COPD) have shown that it significantly reduces problems associated with the disease and is safe.
|Insight into potential new strategy to target skin diseases like psoriasis|
Added: 04.05.2018 17:23 | 0 views | 0 comments
Research has shown that targeting metabolism in growing cells holds promise for the treatment of skin diseases like psoriasis that are characterized by skin overgrowth resulting from excess cell division, known as hyperproliferation.
|Promising new treatment option for chronic plaque psoriasis|
Added: 06.06.2017 15:14 | 0 views | 0 comments
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.